Centessa Pharmaceuticals (CNTA) Stock Price, News & Analysis

Company Overview

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, a bi-specific monoclonal antibody for solid tumors, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; and OX2R Agonists compounds are currently in development for the treatment of narcolepsy. In addition, its products pipeline comprises ORX750, an orally administered selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and earlier-stage preclinical assets and discovery-stage programs. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Key Stats

• Today's Range: $16.14 to $17.07
• 50-Day Range: $14.84 to $19.03
• 52-Week Range: $7.75 to $19.09
• Volume: 755,543 shs
• Average Volume: 957,880 shs
• Market Capitalization: $2.19 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.83
• Consensus Rating: Buy

Centessa Pharmaceuticals Stock Analysis - MarketRank™

Centessa Pharmaceuticals scored higher than 66% of companies evaluated by MarketBeat, and ranked 346th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Centessa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Centessa Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Centessa Pharmaceuticals are expected to grow in the coming year, from ($1.60) to ($1.50) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Centessa Pharmaceuticals is -10.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Centessa Pharmaceuticals is -10.87, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Centessa Pharmaceuticals has a P/B Ratio of 6.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.38% of the float of Centessa Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Centessa Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Centessa Pharmaceuticals has recently decreased by 7.29%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Centessa Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Centessa Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.38% of the float of Centessa Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Centessa Pharmaceuticals has a short interest ratio ("days to cover") of 4.5.

Change versus previous month

Short interest in Centessa Pharmaceuticals has recently decreased by 7.29%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.34

News Sentiment

Centessa Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Centessa Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for CNTA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Centessa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Centessa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,844,812.00 in company stock.

Percentage Held by Insiders

11.59% of the stock of Centessa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.01% of the stock of Centessa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CNTA Stock Analysis - Frequently Asked Questions

How have CNTA shares performed this year?

Centessa Pharmaceuticals' stock was trading at $16.75 at the beginning of 2025. Since then, CNTA stock has decreased by 0.7% and is now trading at $16.63.
View the best growth stocks for 2025 here.

How were Centessa Pharmaceuticals' earnings last quarter?

Centessa Pharmaceuticals plc (NASDAQ:CNTA) posted its earnings results on Tuesday, November, 12th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.42) by $0.05.

When did Centessa Pharmaceuticals IPO?

Centessa Pharmaceuticals (CNTA) raised $285 million in an IPO on Friday, May 28th 2021. The company issued 15,000,000 shares at $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs served as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.

Who are Centessa Pharmaceuticals' major shareholders?

Centessa Pharmaceuticals' top institutional investors include First Light Asset Management LLC (4.40%), Price T Rowe Associates Inc. MD (4.07%), Adage Capital Partners GP L.L.C. (3.88%) and Janus Henderson Group PLC (3.72%). Insiders that own company stock include Antoine Yver, Saurabh Saha, David M Chao, Gregory M Weinhoff, Thomas Templeman, Tia L Bush, Iqbal J Hussain and Harris Rotman.
View institutional ownership trends.

How do I buy shares of Centessa Pharmaceuticals?

Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Centessa Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Centessa Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 3/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CNTA
• CUSIP: N/A
• CIK: 1847903
• Web: www.centessa.com
• Phone: 44-73-9178-9784
• Fax: N/A
• Employees: 200
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $25.83
• High Stock Price Target: $35.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +55.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-151,090,000.00
• Net Margins: N/A
• Pretax Margin: -2,310.33%
• Return on Equity: -52.13%
• Return on Assets: -38.01%

Debt

• Debt-to-Equity Ratio: 0.15
• Current Ratio: 21.52
• Quick Ratio: 21.52

Sales & Book Value

• Annual Sales: $6.85 million
• Price / Sales: 320.10
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.42 per share
• Price / Book: 6.87

Miscellaneous

• Outstanding Shares: 131,850,000
• Free Float: 116,564,000
• Market Cap: $2.19 billion
• Optionable: Optionable
• Beta: 1.53